New treatment and prevention methods for HIV-1 using antibodies
Novel bNAB-based treatment and prevention of HIV-1
This study is exploring a new way to help people with HIV by using special antibodies that can fight off many different strains of the virus, and it's looking to make these antibodies last longer in the body for better protection.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10870028 on NIH RePORTER |
What this research studies
This research focuses on developing a novel approach to treat and prevent HIV-1 infection through the use of broadly neutralizing anti-HIV antibodies (bNAbs). By analyzing the immune responses of HIV-positive individuals, researchers have identified powerful antibodies that can neutralize a wide range of HIV strains. The study aims to enhance the effectiveness of these antibodies by modifying them to improve their longevity in the body. This innovative method could potentially offer a more effective alternative to current HIV treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living with HIV who are seeking new treatment options or those at high risk of HIV infection.
Not a fit: Patients who are not infected with HIV and do not have risk factors for HIV exposure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that significantly reduces HIV infection rates and improves the quality of life for those living with HIV.
How similar studies have performed: Previous research has shown promise in using broadly neutralizing antibodies for HIV treatment, indicating that this approach has potential for success.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Sajadi, Mohammad Mohseni — University of Maryland Baltimore
- Study coordinator: Sajadi, Mohammad Mohseni
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.